Biotech | February 18, 2022
USFDA clears Kairos Pharma’s IND to treat prostrate cancer
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines
Dr. Raman has succeeded Victoria Richon
Evonik invests in start-up to improve patient recovery after open-chest surgery
Virginia will be responsible for meeting client needs for both media and commercial analytics.
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
Darolutamide is developed jointly by Bayer and Orion Corporation
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Resolv ER may remedy leading causes of blindness in adults
Subscribe To Our Newsletter & Stay Updated
